Rock Immune, Inc.
Publicly observedDenver, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Denver | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Rock Immune, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | M35ZNF9XP8Q7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia
USD 400,000.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2021Publicly observed
NIH SBIR/STTR award: CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
USD 248,336.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.